Ollila D W, Brennan M B, Giuliano A E
John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, Calif 90404, USA.
Arch Surg. 1998 Jun;133(6):647-51. doi: 10.1001/archsurg.133.6.647.
To evaluate whether the tumor status of the sentinel lymph node (SN) would alter the systemic adjuvant therapy administered to patients with T1 breast cancer.
Consecutive breast cancer patients (tumors < or = 2 cm) who underwent successful sentinel lymphadenectomy.
Metastatic tumor in the SN, primary tumor size, recommendations for systemic adjuvant therapy before and after histopathologic evaluation of the SN, and actual systemic adjuvant therapy received by the patient.
Of 142 total patients, 14 had T1a tumors; 35, T1b; and 93, T1c. Recommendations for systemic adjuvant therapy were initially determined solely by primary tumor characteristics and menopausal status. These recommendations were compared with recommendations for systemic adjuvant therapy based on tumor characteristics, menopausal status, and SN status; and then were compared with actual systemic adjuvant therapy received by the patient. Among the 118 patients with T1a, T1b, and favorable (positive estrogen or progesterone receptors and a low S-phase percentage with respect to DNA content) T1c tumors, 15 (37.5%) of 40 premenopausal patients and 20 (25.6%) of 78 postmenopausal patients became candidates for chemotherapy when examination of the SN revealed axillary metastasis; chemotherapy was actually administered to all 15 premenopausal patients but to only 6 postmenopausal patients. In the remaining 24 patients with unfavorable T1c tumors, SN status did not change the recommendation for chemotherapy but may have altered the choice of specific chemotherapeutic agents.
Identification of tumor-involved SN may alter systemic adjuvant therapy in patients with T1a, T1b, and favorable T1c tumors and may potentially change the type or dose of chemotherapeutic agents given to patients with unfavorable T1c tumors. Surgical axillary staging of the axilla remains an essential part of breast cancer management and should not be abandoned.
评估前哨淋巴结(SN)的肿瘤状态是否会改变给予T1期乳腺癌患者的全身辅助治疗。
连续纳入成功接受前哨淋巴结切除术的乳腺癌患者(肿瘤≤2 cm)。
SN中的转移性肿瘤、原发肿瘤大小、SN组织病理学评估前后的全身辅助治疗建议以及患者实际接受的全身辅助治疗。
142例患者中,14例为T1a期肿瘤;35例为T1b期;93例为T1c期。全身辅助治疗建议最初仅根据原发肿瘤特征和绝经状态确定。将这些建议与基于肿瘤特征、绝经状态和SN状态的全身辅助治疗建议进行比较;然后与患者实际接受的全身辅助治疗进行比较。在118例T1a、T1b和预后良好(雌激素或孕激素受体阳性且相对于DNA含量的S期百分比低)的T1c期肿瘤患者中,当SN检查显示腋窝转移时,40例绝经前患者中有15例(37.5%)和78例绝经后患者中有20例(25.6%)成为化疗候选者;所有15例绝经前患者实际接受了化疗,但只有6例绝经后患者接受了化疗。在其余24例预后不良的T1c期肿瘤患者中,SN状态未改变化疗建议,但可能改变了特定化疗药物的选择。
识别有肿瘤累及的SN可能会改变T1a、T1b和预后良好的T1c期肿瘤患者的全身辅助治疗,并可能改变给予预后不良的T1c期肿瘤患者的化疗药物类型或剂量。腋窝手术分期仍然是乳腺癌治疗的重要组成部分,不应被放弃。